Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewAnpirtoline hydrochloride is a highly potent 5-HT1B receptor agonist (Ki values are 28, 150 and 1490 nM at 5-HT1B, 5-HT1A and 5-HT2 receptors respectively). Decreases central serotonin synthesis and attenuates aggressive behavior in vivo. Also acts as an antagonist at 5-HT3 receptors (Ki = 29.5 nM) and is brain penetrant.
Anpirtoline hydrochloride is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
分子量 | 265.2 |
公式 | C10H13ClN2S.HCl |
储存 | Desiccate at +4°C |
纯度 | ≥99% (HPLC) |
CAS Number | 99201-87-3 |
PubChem ID | 6917943 |
InChI Key | GRXDJABVNGUGCW-UHFFFAOYSA-N |
Smiles | Cl.ClC1=NC(SC2CCNCC2)=CC=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
water | 100 | ||
DMSO | 26.52 | 100 |
以下数据基于产品分子量 265.2。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 3.77 mL | 18.85 mL | 37.71 mL |
5 mM | 0.75 mL | 3.77 mL | 7.54 mL |
10 mM | 0.38 mL | 1.89 mL | 3.77 mL |
50 mM | 0.08 mL | 0.38 mL | 0.75 mL |
参考文献是支持产品生物活性的出版物。
Almeida and Miczek (2002) Aggression escalates by social instigation or by discontinuation of reinforcement ("frustration") in mice: inhibition by anpirtoline: a 5-HT1B receptor agonist. Neuropsychopharmacology 27 171 PMID: 12093591
Göthert et al (1995) 5HT3 receptor antagonism by anpirtoline, a mixed 5HT1 receptor agonist/5HT3 receptor antagonist. Br.J.Pharmacol. 114 269 PMID: 7881726
Swedberg et al (1992) D-16949 (anpirtoline): a novel serotonergic (5-HT1B) psychotherapeutic agent assessed by its discriminative effect in the rat. J.Pharmacol.Exp.Ther. 263 1015 PMID: 1335050
Watanabe et al (2006) Effects of anpirtoline on regional serotonin synthesis in the rat brain: an autoradiographic study. Nucl.Med.Biol. 33 325 PMID: 16631081
If you know of a relevant reference for Anpirtoline hydrochloride, please let us know.
关键词: Anpirtoline hydrochloride, Anpirtoline hydrochloride supplier, potent, 5-HT1B, agonists, 5-HT3, antagonists, Serotonin, Receptors, 0703, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 Anpirtoline hydrochloride 的部分引用包括:
Gadgaard & Jensen (2020) Functional characterization of 5-HT1A and 5-HT1B serotonin receptor signaling through G-protein-activated inwardly rectifying K+ channels in a fluorescence-based membrane potential assay. Biochem Pharmacol 175 PMID: 32088264
Carvalho-Dias (2017) Serotonin regulates prostate growth through androgen receptor modulation. Sci Rep 7 15428 PMID: 29133842
Müller et al (2009) 5-hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo. PLoS One 4 e6453 PMID: 19649285
您是否知道使用了 Tocris Anpirtoline hydrochloride 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review Anpirtoline hydrochloride and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.